For laboratory research use only. Not for human or veterinary use.

Same-day dispatch on orders before 4 PM ET · Support

GHK-Cu: origin, copper chemistry and research history

Research Library › Copper & Signal

GHK-Cu is the copper(II) complex of GHK (glycyl-L-histidyl-L-lysine), a naturally occurring three-amino-acid peptide found in human plasma. Chemist Loren Pickart isolated it from human plasma in 1973 at the University of California, San Francisco, and its Gly-His-Lys sequence was published in 1977. As of 22 Oct 2026 it is used as a cosmetic ingredient but is not an FDA-approved drug, and injectable GHK-Cu is scheduled for FDA Pharmacy Compounding Advisory Committee review before the end of February 2027.

Key facts

TypeCopper(II) complex of a naturally occurring tripeptide
SequenceGly-His-Lys (glycyl-L-histidyl-L-lysine)
Found inHuman plasma; also reported in saliva and urine
First isolated1973, from human plasma, by Loren Pickart (UCSF)
Structure published1977, Schlesinger, Pickart and Thaler, Experientia
Regulatory status (Oct 2026)Not FDA-approved as a drug; cosmetic ingredient in the U.S.; injectable form due for PCAC review by Feb 2027

Who discovered it

GHK was not designed in a laboratory; it was found in blood. Loren Pickart, working with M. M. Thaler at the Liver Center of the University of California, San Francisco, isolated the tripeptide from human plasma in 1973 [1]. In 1977 Schlesinger, Pickart and Thaler reported its structure as glycyl-histidyl-lysine in the journal Experientia [2].

Pickart continued to publish on the molecule for decades, including a 2015 review of its reported activity in cell-culture and gene-expression studies [3]. Commercial development followed: ProCyte Corporation, a Washington company, was selling copper-peptide formulations by 1998 [4].

Structure and copper chemistry

GHK is a tripeptide of glycine, histidine and lysine. It occurs naturally in human plasma and has also been reported in saliva and urine [3]. The peptide has a strong affinity for copper(II) ions and forms a 1:1 complex, GHK-Cu, which is the form studied in most research and used in commercial ingredients [1, 3].

In the complex, copper is held by three nitrogen atoms from the peptide: the free amino group of glycine, the deprotonated amide nitrogen of the glycine-histidine bond, and a nitrogen of the histidine imidazole ring. The lysine side chain sits outside this core binding site. Inorganic chemists still study the complex; a 2021 paper in Inorganic Chemistry examined how Cu(II)-GHK is reduced by glutathione through short-lived copper-thiolate intermediates [1].

What researchers have studied

Because GHK is a natural molecule, it has no single designed target. In laboratory studies, GHK-Cu has been reported to interact with dermal fibroblasts, the connective-tissue cells that produce collagen, and gene-expression analyses have proposed that it is linked to many cellular pathways [3]. These are preclinical observations. No published human studies of injectable GHK-Cu had been identified as of October 2026 [5].

Why it was investigated

Pickart’s original research question concerned aging liver tissue. He observed that plasma from a younger donor changed the proteins made by liver tissue from an older donor, and he traced that plasma activity to a small copper-binding peptide, later identified as GHK [1, 2]. Later laboratory work examined the complex within tissue-repair research programs [3].

Research timeline

  • 1973: Pickart isolates GHK from human plasma at UCSF [1].
  • 1977: The Gly-His-Lys sequence is published [2].
  • 1998: ProCyte is selling copper-peptide formulations [4].
  • 2015: Pickart and colleagues publish a review of GHK gene-expression and cell studies [3].
  • April 2026: FDA removes injectable GHK-Cu from its Category 2 list [6].
  • By February 2027: FDA Pharmacy Compounding Advisory Committee review scheduled [7].

Regulatory status as of October 2026

As of 22 Oct 2026, GHK-Cu is not approved as a drug anywhere. In the United States it is used as a cosmetic ingredient. Cosmetics do not need FDA approval before sale, but a product intended to treat or prevent disease can be regulated as a drug [8].

In April 2026 the FDA removed injectable GHK-Cu from its Category 2 list of bulk drug substances that raise significant safety concerns, after the nomination was withdrawn. Removal from that list does not authorize compounding [6]. GHK-Cu is one of the substances, along with LL-37, dihexa acetate, melanotan II and PEG-MGF, listed for a meeting of the FDA Pharmacy Compounding Advisory Committee to be held before the end of February 2027 [7]. On 14 Oct 2026 the FDA sent a separate interim compounding policy for certain peptides to the White House for review; its peptide list is not public [9].

GHK-Cu is not named on the 2026 World Anti-Doping Agency Prohibited List [10].

Available from Kalibra Labs

Supplied as a lyophilized research material with a Certificate of Analysis matched to each lot number.

Look up a Certificate of Analysis by lot number →

Frequently asked questions

Who discovered GHK-Cu?

Loren Pickart isolated the GHK peptide from human plasma in 1973 while working at the University of California, San Francisco. He and colleagues published its Gly-His-Lys sequence in 1977.

Is GHK-Cu FDA approved?

No. As of 22 Oct 2026, GHK-Cu is not an FDA-approved drug. It is used as a cosmetic ingredient, and injectable GHK-Cu is scheduled for FDA Pharmacy Compounding Advisory Committee review before the end of February 2027.

What is GHK-Cu made of?

It is the tripeptide glycine-histidine-lysine bound to a copper(II) ion in a 1:1 complex. The copper is held by nitrogen atoms from the glycine and histidine portions of the peptide.

Is GHK naturally occurring?

Yes. GHK is found naturally in human plasma and has also been reported in saliva and urine.

Sources

  1. Ufnalska I, Drew SC, Zhukov I, et al., Bal W. Intermediate Cu(II)-thiolate species in the reduction of Cu(II)GHK by glutathione. Inorg Chem. 2021;60(23):18048–18057. doi:10.1021/acs.inorgchem.1c02669. Link
  2. Schlesinger DH, Pickart L, Thaler MM. Growth-modulating serum tripeptide is glycyl-histidyl-lysine. Experientia. 1977;33:324–325. doi:10.1007/BF02002806. Link
  3. Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. BioMed Res Int. 2015;2015:648108. doi:10.1155/2015/648108. Link
  4. ProCyte Corporation. Form 10-K for fiscal 1998 (filed 1999). U.S. SEC EDGAR. Link
  5. Stone W. The copper peptide trend has gone from creams to injections, ahead of the science. NPR, 7 Sep 2026. Link
  6. Faviero GF, Asebey EJ (Frier Levitt). FDA to remove 12 popular peptides from the Category 2 "do not compound" list. 16 Apr 2026. Link
  7. U.S. FDA. Meeting of the Pharmacy Compounding Advisory Committee (to be held before end of February 2027; LL-37, GHK-Cu, dihexa acetate, melanotan II, PEG-MGF). Link
  8. U.S. FDA. FDA authority over cosmetics: how cosmetics are not FDA-approved, but are FDA-regulated. Link
  9. Office of Information and Regulatory Affairs (reginfo.gov). HHS/FDA, Interim Access Policy for Compounding Using Certain Peptides, RIN 0910-ZD94: received 14 Oct 2026, pending review. Link
  10. World Anti-Doping Agency. 2026 Prohibited List. Link

Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.

For Research Use Only. Kalibra Labs supplies this compound as a lyophilized research material for in-vitro laboratory use. It is not for human or veterinary use and not for use in diagnostic or therapeutic procedures. This page is a scientific and historical reference; it is not medical advice and makes no claim about use in people or animals.

0
Your Cart
Empty CartYour cart is emptyReturn to Shop
Scroll to Top